

(12) **UK Patent Application** (19) **GB** (11) **2 308 545** (13) **A**

(43) Date of Printing by UK Office 02.07.1997

(21) Application No 9707483.5

(22) Date of Filing 25.10.1995

(30) Priority Data

(31) 9421613	(32) 26.10.1994	(33) GB
9422084	02.11.1994	
9425353	15.12.1994	
9517133	22.08.1995	

(86) International Application Data
PCT/EP95/04187 En 25.10.1995

(87) International Publication Data
WO96/13273 En 09.05.1996

(71) Applicant(s)
Novartis AG

(Incorporated in Switzerland)

Schwarzwaldallee 215, CH 4058 Basel, Switzerland

(51) INT CL⁶
A61K 38/13 9/107 9/48

(52) UK CL (Edition O)
A5B BJC BLB B170 B21Y B216 B31Y B317 B822

(56) Documents Cited by ISA
GB 2282586 A EP 0589843 A WO 94/05312 A
DE 004418115 A FR 002678169 A FR 002636534 A

(58) Field of Search by ISA
INT CL⁶ A61K

(72) Inventor(s)
Sylvain Cottens
Barbara Haeberlin
Richard Sedrani
Jacky Vonderscher

(74) Agent and/or Address for Service
B A Yorke & Co
Coomb House, 7 St John's Road, Isleworth,
Middlesex, TW7 6NH, United Kingdom

(54) **Pharmaceutical compositions**

(57) This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising: 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another aspect, this invention provides a pharmaceutical composition for enteral or parenteral administration comprising a macrolide and an acid.